These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. Jeffers MD, Farquharson MA, Richmond JA, McNicol AM. J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782 [Abstract] [Full Text] [Related]
4. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus. Zhai YL, Nikaido T, Toki T, Shiozawa A, Orii A, Fujii S. Br J Cancer; 1999 Jul; 80(10):1658-64. PubMed ID: 10408415 [Abstract] [Full Text] [Related]
5. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas. Allen MM, Douds JJ, Liang SX, Desouki MM, Parkash V, Fadare O. Int J Clin Exp Pathol; 2015 Jul; 8(3):2795-801. PubMed ID: 26045786 [Abstract] [Full Text] [Related]
7. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study. Mikami Y, Hata S, Kiyokawa T, Manabe T. Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209 [Abstract] [Full Text] [Related]
8. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Nola M, Babić D, Ilić J, Marusić M, Uzarević B, Petrovecki M, Sabioncello A, Kovac D, Jukić S. Cancer; 1996 Dec 15; 78(12):2543-50. PubMed ID: 8952563 [Abstract] [Full Text] [Related]
9. p53 alterations in uterine leiomyosarcomas versus leiomyomas. de Vos S, Wilczynski SP, Fleischhacker M, Koeffler P. Gynecol Oncol; 1994 Aug 15; 54(2):205-8. PubMed ID: 8063247 [Abstract] [Full Text] [Related]
10. Chromosome aberrations in uterine smooth muscle tumors: potential diagnostic relevance of cytogenetic instability. Fletcher JA, Morton CC, Pavelka K, Lage JM. Cancer Res; 1990 Jul 01; 50(13):4092-7. PubMed ID: 2354458 [Abstract] [Full Text] [Related]
11. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Bertsch E, Qiang W, Zhang Q, Espona-Fiedler M, Druschitz S, Liu Y, Mittal K, Kong B, Kurita T, Wei JJ. Mod Pathol; 2014 Aug 01; 27(8):1144-53. PubMed ID: 24390224 [Abstract] [Full Text] [Related]
13. [Flow cytometric quantitation of p53 protein expression in gastrointestinal smooth muscle tumors: clinicopathological correlation and prognostic significance]. Cai JH, Jiang YK, Zhang YY. Zhonghua Wai Ke Za Zhi; 1994 Aug 01; 32(8):483-6. PubMed ID: 7882774 [Abstract] [Full Text] [Related]
14. Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice. Strizzi L, Bianco C, Hirota M, Watanabe K, Mancino M, Hamada S, Raafat A, Lawson S, Ebert AD, D'Antonio A, Losito S, Normanno N, Salomon DS. J Pathol; 2007 Jan 01; 211(1):36-44. PubMed ID: 17072826 [Abstract] [Full Text] [Related]
16. [Expression of bcl-2 and bax protein in uterine leiomyosarcomas and leiomyomas]. Zhang ZL, Zhang Y, Zhou JH. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Apr 01; 30(2):183-6. PubMed ID: 15898430 [Abstract] [Full Text] [Related]
18. Transforming growth factor-alpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3F1 mice. Moore AB, He H, Yoshida A, Rico PJ, Haseman JK, Dixon D. Exp Toxicol Pathol; 2000 Jun 01; 52(3):195-200. PubMed ID: 10930119 [Abstract] [Full Text] [Related]